Feasibility and potential clinical benefit of dose de-escalation in stereotactic ablative radiotherapy for lung cancer lesions with ground glass opacities
The study lays the foundation for an eventual use of dose de-escalation in SABR for treating lung lesions with GGO, potentially leading to equivalent local control while reducing associated toxicities. These findings lay the groundwork for future clinical trials.
Authors
- Carles Gomà (ORCID: https://orcid.org/0000-0003-0336-390X)
- Marcelo Sánchez (ORCID: https://orcid.org/0000-0002-5754-7723)
- C. Cases (ORCID: https://orcid.org/0000-0003-2110-9016)
- Mariana Benegas (ORCID: https://orcid.org/0000-0003-0585-5609)
- Meritxell Mollà (ORCID: https://orcid.org/0000-0001-6215-2251)
- Gabriela Antelo (ORCID: https://orcid.org/0000-0001-6394-7750)
- Sergi Serrano-Rueda (ORCID: https://orcid.org/0000-0002-3288-3536)
- Marc Ballestero
Institutions
- Consorci Institut D'Investigacions Biomediques August Pi I Sunyer (ES)
- Universitat de Barcelona (ES)
Publication Details
- Journal
- Physics and Imaging in Radiation Oncology
- Published
- 2024-10-01
- DOI
- https://doi.org/10.1016/j.phro.2024.100681
- Primary Topic
- Lung Cancer Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00